On the other hand, SPRINT explicitly excluded patients with diabetes.  In some Asian countries, stroke is more common than cardiac diseases as the cause of CV deaths. Whether intensive SBP control has similar, greater, or less CV- protective effects in the Asian CKD population is unclear and may require con rmation.  Although there is strong evidence that ambulatory or home BP measurements are better predictors of adverse outcomes than of ce BP, all large RCTs on BP targets in adults employed standardized of ce BP. RCTs targeting home or ambulatory BP measurements are needed.  SGLT2 inhibitors have major CV, kidney, and survival bene ts among patients with CKD. In addition to reducing BP, they cause an early, acute fall in GFR, a pattern that is also observed in intensive SBP lowering. The effects of these drugs, in combination with intensive BP-lowering therapy on CV outcomes, all-cause mortality, cognition, as well as acute and chronic changes in kidney function, require further examination.  There is a strong need for implementation research on locally acceptable strategies to increase adherence to guideline-based BP-lowering treatment (e.g., polypills). 3.2 Treatment with antihypertensive drugs, including RAS inhibitors (RASi) This section makes recommendations on which medications to use for treatment of high BP in patients with CKD, with and without diabetes, with and without albuminuria. The recom- mendations presented in this section governing initiation of RASi apply only to CKD G1 G4 since there is currently no RCT evidence on the use of these agents in CKD G5. The bene ts and harms of initiation, continuation, or discontinuation of RASi in CKD G5 have not been tested in RCTs. The evidence review included an assessment of subgroups based on the amount of albuminuria (A1 [ACR <30 mg/g or 3 mg/mmol], mg/mmol], respectively). 